secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2025-04-23T23:59:59+00:00
Accession:  0001099800-25-000020
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Q1 sales $1.41B (+6.2%), TMTT surging 58%, guidance raised
------------------------------------------------------------------

- Q1 sales $1.41B (+6.2% reported, +7.9% adjusted); GAAP EPS $0.62, adjusted EPS $0.64.
- TAVR sales $1.05B (+3.8%, +5.4% constant currency); TMTT sales $115M (+58%).
- Gross margin 78.7%; operating margin 27.9% (adj. 29.1%) on favorable mix and delayed expenses.
- 2025 guidance: total sales raised to $5.7-6.1B; TMTT raised to $530-550M; adj. EPS reaffirmed $2.40-2.50.
- Q2 guidance: sales $1.45-1.53B, adj. EPS $0.59-0.65; CE Mark SAPIEN M3, NCD for EVOQUE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980025000020/0001099800-25-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980025000020/ew-20250423.htm
  HTML page:      https://secwatch.observer/filing/0001099800-25-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer